Expertise in
3
conditions

Dr. Aida Lugo

Dermatology
Office
410 Market St Ste 400, 
Chapel Hill, NC 
Referral may be required
Before you request
Expertise in
3
conditions
Office
410 Market St Ste 400, 
Chapel Hill, NC 

Overview

Aida Lugo is a Dermatologist practicing medicine in Chapel Hill, North Carolina.

Dr. Lugo is highly rated in 3 conditions, according to our data. Her clinical expertise encompasses Contact Dermatitis, Psoriasis, Actinic Keratosis, and Epidermolysis Bullosa.

She is actively involved in clinical research, co-authoring 25 peer reviewed articles and participating in 10 clinical trials.

Graduate Institution

University Of Puerto Rico School Of Medicine

Specialties

Dermatology

Licenses

Dermatology in PR

Hospital Affiliations

Unc Hospitals

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
TeamCare
  • OTHER COMMERCIAL
Trillium
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

Office
410 Market St Ste 400, Chapel Hill, NC 27516
Other Locations
Office
Chapel Hill, NC 27599

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Multicenter, Randomized, Double-Blind, Placebo- Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
A Multicenter, Randomized, Double-Blind, Placebo- Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
Enrollment Status: Completed
Publish Date: April 07, 2026
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Randomized, Double-Blind, Vehicle-Controlled, Sample Size Adaptive Design Study to Evaluate the Safety and Efficacy of Topically Applied EB01 Cream in Healthy Adult Volunteers and Adult Subjects with Moderate to Severe Chronic Allergic Contact Dermatitis
A Randomized, Double-Blind, Vehicle-Controlled, Sample Size Adaptive Design Study to Evaluate the Safety and Efficacy of Topically Applied EB01 Cream in Healthy Adult Volunteers and Adult Subjects with Moderate to Severe Chronic Allergic Contact Dermatitis
Enrollment Status: Completed
Publish Date: November 14, 2024
Intervention Type: Drug
Study Drug: EB01 Cream
Study Phase: Phase 2
A Multicenter, Long-Term Extension to Evaluate the Long-term Safety and Maintenance of Treatment Effect of LY3074828 in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-3
A Multicenter, Long-Term Extension to Evaluate the Long-term Safety and Maintenance of Treatment Effect of LY3074828 in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-3
Enrollment Status: Terminated
Publish Date: March 21, 2023
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Pivotal Study to Evaluate the Safety and Efficacy of VP-102 Topical Film-Forming Solution [0.7% (w/v) Cantharidin] in Subjects (2 Years and Older) With Molluscum Contagiosum
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Pivotal Study to Evaluate the Safety and Efficacy of VP-102 Topical Film-Forming Solution [0.7% (w/v) Cantharidin] in Subjects (2 Years and Older) With Molluscum Contagiosum
Enrollment Status: Completed
Publish Date: January 11, 2022
Intervention Type: Combination product
Study Phase: Phase 3
Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of Ixekizumab in Patients From 6 to Less Than 18 Years of Age With Moderate-to-Severe Plaque Psoriasis
Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of Ixekizumab in Patients From 6 to Less Than 18 Years of Age With Moderate-to-Severe Plaque Psoriasis
Enrollment Status: Completed
Publish Date: September 27, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of Mirikizumab to Secukinumab and Placebo in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of Mirikizumab to Secukinumab and Placebo in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-2
Enrollment Status: Completed
Publish Date: March 30, 2021
Intervention Type: Drug
Study Phase: Phase 3
A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-to-Severe Plaque Psoriasis
A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-to-Severe Plaque Psoriasis
Enrollment Status: Completed
Publish Date: July 28, 2020
Intervention Type: Drug
Study Phase: Phase 4
A Phase 3, Multi-center, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of SD-101 Cream in Patients With Epidermolysis Bullosa
A Phase 3, Multi-center, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of SD-101 Cream in Patients With Epidermolysis Bullosa
Enrollment Status: Completed
Publish Date: April 09, 2020
Intervention Type: Drug
Study Phase: Phase 3
An International, Multicenter, Randomized, Double-Blind, Parallel-Group Phase 2 Study Evaluating the Safety and Efficacy of Diacerein 1% Ointment Topical Formulation in Subjects With Epidermolysis Bullosa Simplex
An International, Multicenter, Randomized, Double-Blind, Parallel-Group Phase 2 Study Evaluating the Safety and Efficacy of Diacerein 1% Ointment Topical Formulation in Subjects With Epidermolysis Bullosa Simplex
Enrollment Status: Terminated
Publish Date: November 05, 2019
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2 Multicenter Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of Asimadoline in Adult Subjects With Pruritus Associated With Atopic Dermatitis
A Phase 2 Multicenter Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of Asimadoline in Adult Subjects With Pruritus Associated With Atopic Dermatitis
Enrollment Status: Completed
Publish Date: December 13, 2017
Intervention Type: Drug
Study Phase: Phase 2
View 9 Less Clinical Trials

25 Total Publications

Potential Allergens in Feminine Hygiene Products.
Potential Allergens in Feminine Hygiene Products.
Journal: Dermatitis : contact, atopic, occupational, drug
Published: September 30, 2025
Similar Doctors
Expertise in
19
conditions
Expertise in
19
conditions
Referral required

Duke Pediatric Dermatology Patterson Place

5324 McFarland Rd, 
Durham, NC 
 (6.4 miles away)
919-401-7733
Experience:
23+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Daniela Kroshinsky is a Dermatologist practicing medicine in Durham, North Carolina. She has been practicing medicine for over 23 years. Dr. Kroshinsky is highly rated in 19 conditions, according to our data. Her clinical expertise encompasses Calciphylaxis, Cellulitis, Calcinosis, and Acute Febrile Neutrophilic Dermatosis. Dr. Kroshinsky is board certified in American Board Of Dermatology, Dermatology.

Expertise in
9
conditions
Dr. Auris Huen
Dermatology
Expertise in
9
conditions
Dr. Auris Huen
Dermatology
Referral may be required

UT MD Anderson Cancer Center

210 Ashville Ave # 408, 
Cary, NC 
 (19.4 miles away)
713-792-6161
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Auris Huen is a Dermatologist practicing medicine in Cary, North Carolina. Dr. Huen is highly rated in 9 conditions, according to our data. Her clinical expertise encompasses Mycosis Fungoides, T-Cell Lymphoma, Cutaneous T-Cell Lymphoma (CTCL), Lymphomatoid Papulosis, and Thymectomy.

Expertise in
8
conditions
Dr. Donna Culton
Dermatology
Expertise in
8
conditions
Dr. Donna Culton
Dermatology
Referral required

Office

410 Market St Ste 400, 
Chapel Hill, NC 
 (0.1 miles away)
919-966-2485
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Donna Culton is a Dermatologist practicing medicine in Chapel Hill, North Carolina. Dr. Culton is highly rated in 8 conditions, according to our data. Her clinical expertise encompasses Lichen Planus, Bullous Pemphigoid, Pemphigus, and Pemphigus Vulgaris.

Frequently Asked Questions about Dr. Aida Lugo

How do I make an appointment with Dr. Aida Lugo?

You can book an appointment with Dr. Aida Lugo by calling their office at 919-966-2485. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Aida Lugo a top-rated expert for Contact Dermatitis?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Aida Lugo is classified as an Advanced expert for Contact Dermatitis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Aida Lugo specialize in?

While Dr. Aida Lugo is a Dermatology, they have specific expertise in Contact Dermatitis, Psoriasis, and Actinic Keratosis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Dermatology.

Does Dr. Aida Lugo participate in research or clinical trials?

Yes. Dr. Aida Lugo has published 25 articles and abstracts on conditions like Contact Dermatitis. You can view a list of Dr. Aida Lugo's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Aida Lugo accept my insurance?

Dr. Aida Lugo accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 919-966-2485 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Lugo's expertise for a condition
ConditionClose
      View All 22 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile